N/A N=128 To Investigate the Gingivitis Efficacy of a Stannous Fluoride Dentifrice in a Chinese Population
Gingivitis
Primary: Mean Bleeding Index (BI) — 0.07; 0.15 Score on Scale — p=<.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=140 Improving Mood in Veterans in Primary Care
Depression
Primary: Change From Baseline in Depressive Symptoms at 12 Weeks — 15.68; 15.93; 11.40; 12.56 score on a scale — p=<0.05
N/A N=49 Bilateral Prefrontal Modulation in Alcoholism
Drug Addiction · Executive Dysfunction
Primary: Craving — 5.522; 3.818; 4.391; 4.136 scores — p=< 0.01
Phase 1 N=52 A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Capsule and Tablet Formulation in Healthy Participants
Healthy Participants
Primary: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Esomeprazole — 1908.0; 1922.2 hour*nanogram per milliliter (h*ng/mL)
Phase 2 N=86 Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial
Nocturia
Primary: Change in Nocturia Episodes — 3.6; 3.3; 3.9; 3.6 average nightly voids — p=0.0017
N/A N=20 Real-Time fMRI Feedback Effects on Pain Perception
Cognitive Pain Control
Primary: Average Unpleasantness — 3.75; 3.56; 3.30; 4.28 units on a scale
Phase 1 N=25 Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Lung Cancer · Non-small Cell Lung Cancer (NSCLC)
Primary: Maximum Tolerated Dose (MTD) of Afatinib (BIBW 2992) in Combination With Dasatinib — 30; 100 mg
Phase 1 N=116 Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole — 515.7; 519.5; 1027.0; 978.6 nanogram/milliliter (ng/mL) — p=0.5535
Phase 1 N=45 A Study of LY2951742 in Healthy Japanese and Caucasian Participants
Migraine Disorders
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 2 N=390 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine
Dengue · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2 — 5.38…
N/A N=32 everlinQ Endovascular Access System Enhancements (EASE) Study
Chronic Kidney Diseases
Primary: Number of Participants With Protocol-Defined endoAVF Maturation — 29 Participants
Phase 3 N=1,656 Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Primary: Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL — 1.19; 1.03; 1.24 Exacerbations per year — p=0.6490
Phase 2 N=14 Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer
Ovarian Cancer
Primary: Number of Participants With Dose-Limiting Toxicities — 0; 0; 0 Participants
Phase 4 N=40 Effects of Modafinil in Methamphetamine Dependence
Methamphetamine Dependence
Primary: Percentage of Participants With Methamphetamine-positive Urine Drug Screens — 85; 65 Percentage of participants
Phase 3 N=403 A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Small Cell Lung Carcinoma
Primary: Duration of Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1 in the Global Population — 4.3; 5.2 Months — p=0.0170